Treatment Trials

1 Clinical Trials for Various Conditions

Focus your search

      TERMINATED
      ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment
      Description

      This randomized phase IIb trial studies how well ACTOplus met extended release (XR) works in treating in patients with stage I-IV oral cavity or oropharynx cancer that are undergoing definitive treatment. Chemoprevention is the use of drugs to keep oral cavity or oropharynx cancer from forming or coming back. The use of ACTOplus met XR may slow disease progression in patients with oral cavity or oropharynx cancer.

      Conditions
      Oral Cavity NeoplasmOropharyngeal NeoplasmStage 0 Oral Cavity Squamous Cell Carcinoma American Joint Committee on Cancer (AJCC) v6 and v7Stage 0 Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7Stage I Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
      Talk to us